A New Era in Alzheimer’s Innovation

Closing General Session: A New Era in Alzheimer’s Innovation

Sponsored by PhRMA

Presented by AARP

 

 

 
 

Thursday, March 29 | 8:00–9:30 AM

Alzheimer's disease devastates the minds of patients, creates substantial burdens for families and caregivers and costs the United States billions of dollars each year.  The disease itself is one of the most complex researchers have ever studied.  Despite that, America's biopharmaceutical companies are committed to combatting this devastating disease, with 87 potential new treatments in clinical trials today. However, the path from research to a new medicine is extremely long and complex with many setbacks along the way, particularly in the case of Alzheimer's. Scientists have made progress in unraveling the complexities of the brain and identifying the underpinnings of Alzheimer's, but finding an effective treatment remains a daunting challenge.  Join us to learn more about what the biopharmaceutical industry is doing in the search for treatments and hopefully one day, a cure and the impact this is having on patient's lives.

This session will educate audience members on the work the industry is doing to search for treatments and cures in the Alzheimer's space and beyond, expand on the difficulty of researching and bringing medicines to market, including the high number of failures, and highlight the patient experience and the need for access to therapies. 

Moderated by Lori Reilly, JD, Executive Vice President for Policy, Research & Membership, PhRMA

Presenters: Bob Blancato, MPA, President, Matz, Blancato & Associates; Phyllis Ferrell, MBA, Vice President of the global Alzheimer's Disease Team, Eli Lilly And Company; Eric Karran, PhD, VP, Distinguished Research Fellow, Foundational Neuroscience Center, Abb Vie Inc; Matthew Kennedy, PhD, Director, Early Discovery Neuroscience, Merck & Co. Inc; Brian Kursonis, Founder, withALZmyHeart.com; Jason Resendez, Executiver Director, LatinosAgainstAlzheimer's Coalition and Chief of Staff, UsAgainstAlzheimer's.